biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Nov 21, 2018 8:51pm

77 Views

Post# 29007908

RE:RE:RE:RE:RE:News: Lymphing along to better days...Links

Thanks for the thorough reply JD. Good background to put this in context. Still, I agree with bfw 100% that the news release could have been worded better to circumvent confusion on the BBB/brain accumulation issue. I clearly wasn't the only one who was looking for discussion of that issue in this news release. At first read I was more distracted by the lack of this BBB/brain accumulation issue than appreciating the peripheral distribution story. BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale